Caris Life Sciences IPO
Caris Life Sciences is a molecular diagnostics company that provides comprehensive tumor profiling to guide personalized cancer treatment. The company's tests analyze DNA, RNA, and proteins to match patients with targeted therapies. Caris has raised significant funding and has been exploring a public listing.
What We Know
Caris Life Sciences IPO'd on the Nasdaq under ticker CAI in June 2025 at $21 per share, raising $494.6 million. The molecular diagnostics company provides comprehensive tumor profiling for personalized cancer treatment. The IPO was one of the largest healthcare listings of 2025.
Frequently Asked Questions
Has Caris Life Sciences had an IPO?
Yes, Caris Life Sciences has already gone public. The company IPO'd on the Nasdaq under ticker CAI in June 2025 at $21 per share.
When is the Caris Life Sciences IPO date?
Caris Life Sciences' IPO date was June 18, 2025. The company raised $494.6 million in one of the largest healthcare IPOs of 2025.
How can I buy Caris Life Sciences stock?
You can buy Caris Life Sciences stock (CAI) through any major brokerage account. The company trades on the Nasdaq.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts